Top Stock Reports For Home Depot, Abbott & Bristol-Myers
Zacks Investment Research | Aug 21, 2019 02:04AM ET
Wednesday, August 21, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 16 major stocks, including Home Depot (NYSE:HD), Abbott (ABT) and Bristol-Myers (BMY). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see
Home Depot’s shares have gained +21% year to date, outperforming the Zacks Retail Building Products industry’s +19.5% increase. The Zacks analyst thinks that this is attributable to a robust earnings surprise trend recorded for more than five years, which continued in second-quarter fiscal 2019.
Earnings benefited from progress on strategic investments as well as a favorable U.S. consumer backdrop and a steady housing market. Meanwhile, the company’s top line lagged estimates but improved year over year on robust comps performance. Its efforts to provide an interconnected shopping experience to customers, with innovative products and improved productivity, position it for growth.
Despite these gains, lumber price deflation remained a drag on the company’s sales and comps in the fiscal second quarter. Further, it slashed its sales and comps view for fiscal 2019 on lumber price deflation and fears of potential impacts of the newly enacted tariffs.
(You can ).
Shares of Abbott have gained +30.2% over the past year, significantly outperforming the Zacks Medical Products industry, which has increased +3.2% over the same period. Abbott exited second quarter 2019 with better-than-expected earnings. However, revenues lagged the estimates.
The Zacks analyst is optimistic about the strong and consistent EPD and Medical Devices performance. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. This apart, synergies from Alere consolidation in the form of Rapid Diagnostics have been driving growth. Within Structural Heart, worldwide uptake of MitraClip therapy improves further.
Meanwhile, the company’s emerging market performance has been promising. Consequently, Abbott has raised its full-year guidance. On the flip side, sluggish Rhythm Management arm in the United States continues to dent growth. Increasing currency headwind is another downside.
Get The News You Want
(You can ).
Bristol-Myers’ shares have underperformed the Zacks Large Cap Pharmaceuticals industry in the year-to-date period, losing -8.7% vs. -2.1%. The Zacks analyst thinks Bristol-Myers’ lead immuno-oncology drug, Opdivo, continues to drive growth. Label expansion of Opdivo into additional indications should further boost the top line. Empliciti and Sprycel are also performing well.
Bristol-Myers also has presence in other core therapeutic areas, including immunoscience and cardiovascular. Blood thinner drug, Eliquis, is expected to drive further growth, propelled by increased share in the novel oral anticoagulant (NOAC) market.
The impending acquisition of Celgene Corporation (NASDAQ:CELG) will broaden Bristol-Myers’ oncology portfolio with the addition of blockbuster drug, Revlimid. However, pipeline setbacks are a concern. The failure of the part 2 of the Checkmate-227 study was disappointing, given the potential in the NSCLC market.
(You can ).
Other noteworthy reports we are featuring today include Activision (ATVI), MPLX LP (MPLX) and Marathon Petroleum (MPC).
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Note: Our Director of Research Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
Per the Zacks analyst, Activision's solid portfolio comprising Call of Duty, Overwatch and King's Candy Crush is helping it to steer past intensifying competition.
While the successful integration of Andeavor's operations bode well for Marathon Petroleum, the Zacks analyst is worried over the projected plant turnaround costs in the third quarter.
The Zacks analyst believes that MPLX is well positioned to cash in on transportation capacity constraints in the prolific Permian, courtesy of its growing network of natural gas pipelines.
Per the Zacks analyst, Principal Financial should benefit from sturdy retirement and long-term savings, and solid global asset management.
Per the Zacks analyst Aqua America's systematic capital investment is resulting in organic growth of the company.
Per the Zacks analyst, Reinsurance Group is set to grow from solid in-force business generating predictable long-term earnings risk.
Per the Zacks analyst, in the current volatile interest rate and high prepayment environment, AGNC Invesmtent's commitment to reposition the portfolio will likely optimize its performance.
Per the Zacks analyst, Activision's solid portfolio comprising Call of Duty, Overwatch and King's Candy Crush is helping it to steer past intensifying competition.
While the successful integration of Andeavor's operations bode well for Marathon Petroleum, the Zacks analyst is worried over the projected plant turnaround costs in the third quarter.
The Zacks analyst believes that MPLX is well positioned to cash in on transportation capacity constraints in the prolific Permian, courtesy of its growing network of natural gas pipelines.
Per the Zacks analyst, Principal Financial should benefit from sturdy retirement and long-term savings, and solid global asset management.
Per the Zacks analyst Aqua America's systematic capital investment is resulting in organic growth of the company.
Per the Zacks analyst, Reinsurance Group is set to grow from solid in-force business generating predictable long-term earnings risk.
Per the Zacks analyst, in the current volatile interest rate and high prepayment environment, AGNC Invesmtent's commitment to reposition the portfolio will likely optimize its performance.
New Upgrades/h6
Despite increased expenses, the Zacks analyst is encouraged by Carnival's effort to enhance revenue yield from high ticket prices amid increased demand.
Per Zacks analyst, Gap is enhancing omni-channel capabilities and has increased online presence across its brands. Robust online trends with higher traffic and conversions are likely to fuel sales.
Per the Zacks analyst, Waddell & Reed's efforts to strengthen wealth management channel and asset inflows will likely aid revenues. Efficient capital deployment plan reflect solid liquidity position.
Despite increased expenses, the Zacks analyst is encouraged by Carnival's effort to enhance revenue yield from high ticket prices amid increased demand.
Per Zacks analyst, Gap is enhancing omni-channel capabilities and has increased online presence across its brands. Robust online trends with higher traffic and conversions are likely to fuel sales.
Per the Zacks analyst, Waddell & Reed's efforts to strengthen wealth management channel and asset inflows will likely aid revenues. Efficient capital deployment plan reflect solid liquidity position.
New Downgrades/h6
Per the Zacks analyst, Amphenol suffers from lower demand for its products in communications equipment, automotive and industrial end-markets and ongoing U.S.-China trade war.
Per the Zacks analyst, continued weakness in Mettler-Toledo's food retail segment due to unfavorable customer project timing are hurting sales in Americas and Europe.
Per the Zacks analyst, higher markdowns is the key reason for Dillard's soft margins and bottom line growth in recent years. Markdowns mainly stem from high inventory levels at stores.
Per the Zacks analyst, Amphenol suffers from lower demand for its products in communications equipment, automotive and industrial end-markets and ongoing U.S.-China trade war.
Per the Zacks analyst, continued weakness in Mettler-Toledo's food retail segment due to unfavorable customer project timing are hurting sales in Americas and Europe.
Per the Zacks analyst, higher markdowns is the key reason for Dillard's soft margins and bottom line growth in recent years. Markdowns mainly stem from high inventory levels at stores.
undefined Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.